Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout

Data From Second Phase III, US Filing Expected In 2024

The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.

Crinetics Pharmaceuticals, Inc.’s paltusotine succeeded in the first of two Phase III clinical trials in acromegaly, showing that patients switching from standard-of-care monthly injectable somatostatin analogs (SSAs) maintained disease control with a once-daily oral therapy. The readout boosted confidence in upcoming Phase II and III readouts for the drug and its potential to take center stage as a commercial product that could become a market leader and a new standard of care.

San Diego-based Crinetics reported results from the Phase III PATHFNDR-1 trial on 10 September and after hosting a call on...